Andrew Coles, MD
Interventional Pain Medicine · Farmington, UTNPI 1982721106
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 73 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 19.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $278 and has fallen 84.5% since, to $43 in 2025. That places this record below the midpoint for interventional pain medicine clinicians in UT, where the typical reported total is $7,299.
Across 73 payments — averaging $14.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Collegium Pharmaceutical, Inc.$211
- Amgen$166
- Biodelivery Sciences International, Inc.$111
- Lundbeck LLC$102
- AbbVie$86
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$71
- plus $328 from 17 others
What the payments were for
- Food & beverage$1,075100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 14 | $211 |
| Amgen(2 entities) | 10 | $166 |
| Biodelivery Sciences International, Inc. | 9 | $111 |
| Lundbeck LLC | 7 | $102 |
| AbbVie(2 entities) | 5 | $86 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $71 |
| Lilly USA, LLC | 3 | $42 |
| Pfizer | 2 | $31 |
| Boston Scientific | 2 | $29 |
| Teva Pharmaceuticals USA, Inc. | 2 | $29 |
| Azurity Pharmaceuticals, Inc. | 2 | $26 |
| Merz Pharmaceuticals, LLC | 1 | $19 |
| Vertex | 1 | $19 |
| MDD US Operations, LLC | 1 | $17 |
| Xeris Pharmaceuticals, Inc. | 1 | $14 |
| Averitas Pharma Inc. | 1 | $14 |
| GRT US Holding, Inc. | 1 | $14 |
| Shionogi Inc | 1 | $13 |
| Kaleo, Inc. | 1 | $13 |
| Biohaven Pharmaceuticals, Inc. | 1 | $12 |
| Virtus Pharmaceuticals LLC | 1 | $12 |
| Redhill Biopharma Inc. | 1 | $12 |
| Scilex Pharmaceuticals Inc. | 1 | $11 |
How this compares
$1,075 in reported general payments places this provider in the 10th percentile of 26 interventional pain medicine providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BotoxOnabotulinumtoxina | 13 | $8,561 |
| Buprenorphine | 22 | $4,002 |
| BelbucaBuprenorphine Hcl | 19 | $2,057 |
| Tramadol Hcl ErTramadol Hcl | 29 | $543 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 50 | $494 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 45 | $418 |
| Gabapentin | 24 | $236 |
| Buprenorphine Hcl | 11 | $228 |
| Oxycodone Hcl | 31 | $193 |
| Morphine Sulfate ErMorphine Sulfate | 25 | $182 |
| Pregabalin | 20 | $141 |
| Tramadol Hcl | 42 | $135 |
| Hydromorphone Hcl | 11 | $59 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieBotox | $86 | $8,56113 claims |
| Collegium Pharmaceutical, Inc.Belbuca | $211 | $2,05719 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 10th percentile of 26 interventional pain medicine providers in Utah.
Other interventional pain medicine in Farmington
- Bryan HoelzerVineyard$718K
- Nathan ClementsSaint George$29K
- Rick ObraySt George$23K
- Brian RichardsonLogan$19K
- Alex NelsonMurray$17K
- Steven LarsenSaint George$14K
- J Riley StringhamProvo$13K
- Craig DavisWest Jordan$13K
- Geeta NagpalWest Jordan$11K
- Ashleigh ByrneWest Jordan$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.